We Claim:

1. A composition comprising a TNF-α binding molecule, or a nucleic acid sequence encoding a TNF-α binding molecule, wherein said TNF-α binding molecule comprises; i) a CDRL3 sequence comprising SEQ ID NO: 33, and ii) a CDRH3 comprising SEQ ID NO: 53.

2. The composition of Claim 1, wherein said TNF-α binding molecule further comprises iii) a CDRL1 sequence comprising SEQ ID NO: 15, and iv) a CDRL2 sequence comprising SEQ ID NO: 25.

3. The composition of Claim 2, wherein said TNF-α binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 37, and vi) a CDRH2 sequence comprising SEQ ID NO: 45.

4. The composition of Claim 2, wherein said TNF-α binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 39, and vi) a CDRH2 sequence comprising SEQ ID NO: 45.

5. The composition of Claim 1, wherein said TNF-α binding molecule further comprises iii) a CDRL1 sequence comprising SEQ ID NO: 13, and iv) a CDRL2 sequence comprising SEQ ID NO: 27.

6. The composition of Claim 5, wherein said TNF-α binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 37, and vi) a CDRH2 sequence comprising SEQ ID NO: 55.

7. The composition of Claim 1, wherein said TNF-α binding molecule further comprises a light chain variable region, wherein said light chain variable region comprises a human germline framework region.

8. The composition of Claim 1, wherein said TNF-α binding molecule further comprises a heavy chain variable region, wherein said heavy chain variable region comprises a human germline framework region.

9. A composition comprising a TNF-α binding, or a nucleic acid sequence encoding a TNF-α binding molecule, wherein said TNF-α binding molecule neutralizes human TNF-α cytotoxicity in an in vitro, cell-based assay with an EC_{50} of 2.0×10^{-11} or less.

10. The composition of Claim 9, wherein said TNF-α binding molecule has a binding affinity (K_d) for human TNF-α of 7.5×10^{-12} M or less.

11. The composition of Claim 9, wherein said TNF-α binding molecule has an association rate (kon) for human TNF-α of 3.0×10^{6} M^{-1} s^{-1} or greater.

12. The composition of Claim 9, wherein said TNF-α binding molecule has a dissociation rate (koff) for human TNF-α of 1.0×10^{-4} s^{-1} or less.

13. The composition of Claim 9, wherein said TNF-α binding molecule comprises a light chain variable region, wherein said light chain variable region comprises a human germline framework region.

14. The composition of Claim 9, wherein said TNF-α binding molecule comprises a heavy chain variable region, wherein said heavy chain variable region comprises a human germline framework region.

15. A method treating a TNF-α mediated disease comprising;

a) providing;

i) a subject, and

ii) a composition, wherein said composition comprises TNF-α binding molecules that neutralize human TNF-α cytotoxicity in an in vitro, cell-based assay with an EC_{50} of 2.0×10^{-11} or less; and

b) administering said composition to said subject.

16. The method of Claim 15, wherein said TNF-α mediated disease is selected from sepsis, an autoimmune disease, and rheumatoid arthritis.

17. The method of Claim 15, wherein said TNF-α binding molecules have a binding affinity (K_d) for human TNF-α of 7.5×10^{-12} M or less.

18. The method of Claim 15, wherein said TNF-α binding molecules have an association rate (kon) for human TNF-α of 3.0×10^{6} M^{-1} s^{-1} or greater.

19. The method of Claim 15, wherein said TNF-α binding molecules have a disassociation rate (koff) for human TNFα of 1.0×10^{-4} s^{-1} or less.

20. The method of Claim 15, wherein said TNF-α binding molecule comprises a light chain variable region, wherein said light chain variable region comprises a human germline framework region.

21. The method of Claim 15, wherein said TNF-α binding molecule comprises a heavy chain variable region, wherein said heavy chain variable region comprises a human germline framework region.

22. A composition comprising a TNF-α binding molecule, or a nucleic acid sequence encoding a TNF-α binding molecule, wherein said TNF-α binding molecule comprises at least one of the following CDR sequences; i) a CDRL1 sequence comprising SEQ ID NO:93; ii) a CDRL2 sequence comprising SEQ ID NO:95; iii) a CDRL3 sequence comprising SEQ ID NO: 97; iv) a CDRH1 sequence comprising SEQ ID NO:87; v) a CDRH2 sequence comprising SEQ ID NO:89, and vi) a CDRH3 sequence comprising SEQ ID NO: 91.

23. The composition of Claim 22, wherein said TNF-α binding molecule comprises at least three of said CDR sequences.

24. The composition of Claim 22, wherein said TNF-α binding molecule comprises all six of said CDR sequences.